EMEA-000876-PIP03-14-M05
Key facts
Invented name |
Soliris
|
Active substance |
Eculizumab
|
Therapeutic area |
Neurology
|
Decision number |
P/0514/2020
|
PIP number |
EMEA-000876-PIP03-14-M05
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of neuromyelitis optica spectrum disorders
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com
Tel: +33 147100615 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|